血清 TSH,Tg,TgAb:评估分化型甲状腺癌的三驾马车

2018-05-04 佚名 贝克曼库尔特临床诊断

过去十年,甲状腺癌在世界范围内的发病率呈逐年迅猛上升的趋势。从最新的中国癌症发病率报告来看,2014年国内平均甲状腺癌粗发病率为12.40/10万,在恶性肿瘤发病率排名中居第七位。其中,女性甲状腺癌粗发病率为18.99/10万,数量为男性的4.4倍[1]。甲状腺癌现已成为大城市女性中风险最高的癌症之一。


过去十年,甲状腺癌在世界范围内的发病率呈逐年迅猛上升的趋势。从最新的中国癌症发病率报告来看,2014年国内平均甲状腺癌粗发病率为12.40/10万,在恶性肿瘤发病率排名中居第七位。其中,女性甲状腺癌粗发病率为18.99/10万,数量为男性的4.4倍。甲状腺癌现已成为大城市女性中风险最高的癌症之一。

甲状腺癌发病率为何增长快速?

专家指出,甲状腺癌发病率的升高,除了与放射线、不良生活习惯、家族史等因素有关外,也与检出率的提升有一定关联。过去甲状腺疾病的初步诊断主要依靠医生用手触诊;如今,随着多种检查技术的运用,以及影像学技术的不断提高,再加上体检人群的逐年增加,许多小至1毫米的早期肿瘤都能够被及时发现。

虽然甲状腺癌的发病率较高,但大部分甲状腺癌的预后较好。临床上大类将甲状腺癌分类为分化型甲状腺癌和低分化型甲状腺癌,其中超过90%的甲状腺癌为分化型甲状腺癌(DTC)。DTC的治疗方法主要包括手术治疗、术后131I治疗和TSH抑制,其中手术治疗是首选。做好术前的甲状腺功能评估以及术后评估和随访,对于癌症的评估及预后追踪非常重要。

不论是术前的评估还是术后的评估,相比影像学而言,血清学能更早发现异常。基于此,中国抗癌协会甲状腺癌专业委员会于2017年发布了《甲状腺癌血清标志物临床应用专家共识》,对甲状腺癌血清标志物临床应用提出推荐。针对DTC,《专家共识》中主要推荐了TSH,Tg和TGAb三种血清学标志物。

敲黑板

《共识》推荐

手术前:

所有考虑行手术治疗的甲状腺肿瘤患者,术前均应检测甲状腺功能且包括血清TSH水平。(推荐级别A)

Tg与TgAb可作为甲状腺癌术前常规检测,且建议两者同时检测来作为初始临床状态及血清学指标基线的评估。(推荐级别A)

手术后:

DTC全甲状腺切除术后应常规检测Tg与TgAb,且选择同一厂商的Tg和TgAb检测试剂,建议连续检测用于持续评估术后复发风险及治疗反应。(推荐级别A)

术后持续监测血清Tg与TgAb,对动态风险分层进行持续评估,指导DTC随访方案及治疗决策的调整。(推荐级别A)

划重点

TSH在甲功中的重要性大家已经非常熟悉了。那么我们就来说说另外两个,也是《共识》中重点推荐的指标:甲状腺球蛋白,抗甲状腺球蛋白抗体。

甲状腺球蛋白Tg是由甲状腺滤泡上皮分泌,主要储存在甲状腺滤泡腔。Tg可评估术前甲状腺癌初始临床状态,以及监测DTC手术后肿瘤的复发。正常来说,甲状腺全切除后,血清Tg应降到几乎测不到的水平;在术后随访中若发现Tg水平一直升高,则提示有转移灶的发生。

TgAb是抗甲状腺球蛋白抗体。正常情况下,分化型甲状腺癌患者的TgAb水平会在根治术后逐渐降低,如果TgAb水平再次升高,往往会提示肿瘤复发,医生会建议做进一步的影像学等检查。

与此同时,血清Tg的检测会直接受到体内TgAb水平的影响。因此在检测Tg时应同时检测TgAb,并选择同一厂家的Tg和TgAb检测试剂,以避免不同厂家试剂盒设计所带来的差异,以确保实现更加精准的评估。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2019-09-08 123ba698m96暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-09 大爰

    学习了谢谢分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-07 changjiu

    学习一下谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 xinxin088
  6. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 zhangpaul93
  7. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=372463, encodeId=a4253e246338, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Sun Sep 08 21:10:22 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313502, encodeId=92e4313502a9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed May 09 13:06:15 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312935, encodeId=f66331293510, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 07 21:30:54 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407800, encodeId=390d140e8005a, content=<a href='/topic/show?id=e0731e891b9' target=_blank style='color:#2F92EE;'>#TSH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17891, encryptionId=e0731e891b9, topicName=TSH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530185, encodeId=831b1530185f3, content=<a href='/topic/show?id=902d1e338b5' target=_blank style='color:#2F92EE;'>#TgAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17338, encryptionId=902d1e338b5, topicName=TgAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Sun May 06 10:36:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312468, encodeId=162531246871, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 06 07:33:20 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312023, encodeId=79ae3120234d, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri May 04 21:07:40 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-04 changjiu

    学习一下谢谢

    0

相关资讯

CLIN CHEM:血清和血浆样品中大麻素的检测新方法

合成大麻素是欧洲毒品和毒瘾监测中心监测的新型精神活性物质中最主要的一组。新型类似物的快速增殖使得对这些新衍生物的检测难度逐渐增大,对开发用于检测这些化合物的所谓“非目标”筛选策略也是近期的热点。 研究人员开发了新的稳定的生物测定法,其中大麻素激活大麻素受体,导致截短的β-抑制蛋白2(βarr2)募集到大麻素受体,与分裂荧光素酶的功能互补,并能够通过生物发光读出。将正常血清(n = 45)和血

血清外泌体检测结直肠癌患者K-Ras基因突变

徐建明教授,解放军第307医院消化肿瘤内科主任、全军肿瘤中心副主任,中国生物医学工程协会靶向药物治疗专委会副主任委员。长期从事肿瘤患者的诊治,坚持推行个体化治疗。2003年至今,利用国际多中心新药临床试验的机会,先后使1000多例患者免费享受到国际最新药物治疗。坚持开展技术创新,在国际上首次提出EGFR靶向药物维持治疗的理论。参与国家多项肿瘤诊疗规范的起草制定。承担国际多中心新药临床研究40余

Ann Neurol:血清神经丝轻链蛋白检测评估多发性硬化治疗效果

血清神经丝轻链蛋白是临床评估多发性硬化患者中枢神经损伤以及治疗效果的敏感的生物标志物

J Clin Periodontol:心肌梗死患者唾液及血清相关生物标志物水平

目的:研究唾液中的半胱氨酸蛋白酶抑制剂C和生长分化因子-15(GDF-15)的心肌标志物与心肌梗死(MI)和牙周状态的关系,并研究唾液和血清心肌标志物之间的关系。

Front Aging Neurosci:脑脊液和血清中miRNA的水平可预测术后谵妄的发生相关

术后谵妄是术后常见并发症,其发生与患者预后不良有关。POD发生的病理生理机制尚不清楚,但是确定其发生的危险因素对术后预后却十分重要。本研究旨在探究术前脑脊液(CSF)和血清中miR-146a、miR-125b及miR-181c与POD的发生及严重程度之间的关系。研究纳入了40名65岁以上行腰麻下全髋/膝关节置换术的老年患者。术前使用简易精神状态检查评估患者基线时期的认知功能。每名患者在术后第一天和

JDI:发现吡格列酮与糖尿病患者血清瘦素水平的关系

根据一篇发表在《糖尿病调查杂志》上的一项分析,与安慰剂相比,吡格列酮与2型糖尿病患者的血瘦素水平显著降低有关。